The Law Offices of Howard G. Smith is continuing its investigation into Alnylam Pharmaceuticals for possible violations of federal securities laws. The investigation follows Alnylam's July 30, 2026 announcement of second quarter 2026 financial results, in which the company lowered its total projected TTR net product revenues by approximately $200 million. Alnylam attributed the reduction to learnings from the initial phase of its launch in the ATTR-CM market, including a normalization of growth in second line volume after satisfying pent-up demand. On that news, Alnylam shares fell as much as $81.25, or 28.35%, in intraday trading on July 30, 2026. Investors who suffered losses are encouraged to contact the law firm to discuss potential claims.
Alnylam Pharmaceuticals IncSecurities fraud investigation and lowered revenue guidance due to launch issues